Myriad Genetics Inc., the maker of tests for hereditary risks of breast and ovarian cancer that lost its patent fight at the U.S. Supreme Court last year, failed to convince a federal court to block a competitor from selling its own genetic tests while another patent-infringement case is pending.
Myriad had asked U.S. District Judge Robert Shelby in Salt Lake City to issue a preliminary injunction to stop Ambry Genetics Corp. from offering its tests while the lawsuit against the company, University of Utah Research Foundation v. Ambry Genetics, is pending. But on Monday the judge issued a 106-page decision in which he said Myriad is unlikely to win lawsuits claiming tests sold by Ambry violate its patents.
